Raf

Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.

ZM 336372 is a potent and selective c-Raf inhibitor.

B-Raf IN 11 is a novel selective inhibitor.

K-Ras-IN-1 is a K-Ras inhibitor.

LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.

PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity.

Anti-Phospho-RAF1 (Ser259) Antibody (5X237) is an antibody targeting Phospho-RAF1 (Ser259). Anti-Phospho-RAF1 (Ser259) Antibody (5X237) can be used in ELISA, WB, IHC, IF.

Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities.

Sulindac sulfide: NSAID targeting COX-1, inhibits Ras-Raf-1 and gamma-secretase (IC50: 20.2 μM), active sulinic acid metabolite.

RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.

SOS1-IN-1 is an inhibitor of SOS1.

Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].

B-Raf IN 13 is a potent B-Raf inhibitor with anticancer activity.B-Raf IN 13 has an IC50 of 3.55 nM in the BRAF V600E enzyme assay.

XL-281: potent oral RAF kinase inhibitor, effective on wild-type and mutants, reduces tumor growth and cell proliferation, increases apoptosis.

MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors.

6H05 (K-Ras inhibitor) is a selective, allosteric inhibitor of oncogenic mutant K-Ras(G12C).

Raf inhibitor 2 (CID 25014542) is novel inhibitor of Raf kinases.

Raf inhibitor 1 dihydrochloride (B-Raf inhibitor 1 dihydrochloride) is a potent and selective B-Raf inhibitor.

SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.

Effusanin A: antibacterial, damages DNA, inhibits DU145 cells at 3.16 μM and LoVo cells at 3.02 μM.

Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57

Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.

PLX7904 (PB04), a selective RAF inhibitor, blocks ERK1/2 in mutant BRAF melanoma without activating it in RAS mutants.

SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.

L-779450, an effective, ATP-competitive Raf kinase inhibitor (IC50: 10 nM) , displays >7, >30 and >70-fold selectivity over p38α, GSK3β and Lck respectively.

Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.

B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.

GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor.

TBAP-001 is a RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay and an IC50 of 18 nM in Cell-Based Phosho-ERK Assay.

TAK-632 is a potent pan-Raf inhibitor.

Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).

B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.

PLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf.Cost-effective and quality-assured.

Regorafenib HCl (BAY73-4506) is an oral inhibitor targeting angiogenic, stromal, and cancer kinases with strong antitumor effects.

Vem-L-Cy5 (compound 3), a Vemurafenib-based BRAF inhibitor conjugated with the near-infrared (NIR) fluorophore cyanine-5 (Cy5), selectively targets the BRAF

AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.

Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF.Cost-effective and quality-assured.

Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.

Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally

Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant

BRAF inhibitor is an inhibitor of B-Raf.

Lonafarnib (Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).

SKLB646 is an orally active multitarget kinase inhibitor that exhibits potent suppression of several kinases. It demonstrates significant inhibitory effects on SRC and VEGFR2, with IC50 values of 0.002 μmol/L and 0.012 μmol/L, respectively. Additionally, SKLB646 shows notable inhibition of B-Raf and C-Raf, with IC50 values of 0.022 μmol/L and 0.019 μmol/L, respectively. The compound inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinases. Furthermore, SKLB646 inhibits the proliferation, migration, and invasion of human umbilical vein endothelial cells (HUVEC), thereby suppressing tumor-induced angiogenesis. SKLB646 also displays significant anti-proliferative and anti-survival effects on triple-negative breast cancer (TNBC) cell lines.

Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.

Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.

PROTAC BRAF-V600E degrader-1 (Compound 23) selectively induces degradation of BRAF-V600E but not wildtype BRAF.

GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.

MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).

B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.

GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well.

Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.

B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor.

RAF265 (CHIR-265) inhibits C-Raf/B-Raf/V600E (IC50: 3-60 nM), blocks VEGFR2 (EC50: 30 nM), in Phase 2 trials.

SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay).

SOS1-IN-11 is an effective inhibitor of SOS1 (IC50 = 30 nM).

Anti-Phospho-RAF1 (Ser621) Antibody (2K681) is an antibody targeting Phospho-RAF1 (Ser621). Anti-Phospho-RAF1 (Ser621) Antibody (2K681) can be used in ELISA, WB, IF.

Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently.

Anti-Phospho-RAF1 (Ser43) Antibody (8R108) is an antibody targeting Phospho-RAF1 (Ser43). Anti-Phospho-RAF1 (Ser43) Antibody (8R108) can be used in ELISA, IF.

RMC-0331 (RM-023) is an oral SOS1 inhibitor with potential to block RAS activation and anticancer properties.

AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor.

Regorafénib N-oxyde M2 is an active metabolite of Regorafenib.

NST-628 is a pan-RAF-MEK molecular glue that prevents RAF from phosphorylating and activating MEK. NST-628 inhibits the RAF-MEK signaling complex.

Plixorafenib (PLX8394) is an orally active inhibitor of the serine/threonine protein kinase B-Raf (BRAF) protein.Cost-effective and quality-assured.